Skip to content
OpenCapital
Get started

Viatris VTRS Creon ® — Net Sales

Other product segments

Brands
$2.33B+10.2%
Generics
$1.18B+4.5%
Lipitor
$462M+19.1%
Norvasc
$210M+21.9%
Lyrica ®
$120.6M+7.1%
EpiPen® Auto-Injectors
$101.1M+4.6%
Viagra ®
$95M-3.6%
Zoloft ®
$72.6M+20.6%
Celebrex ®
$67.1M+5.8%
Yupelri ®
$62.5M+7.2%
Effexor ®
$62M+4.6%
Xalabrands
$39.2M+5.7%
Dymista ®
$37.3M-12.9%
Xanax ®
$34.8M+7.7%

Similar metrics at other companies

ANI Pharmaceuticals logo
ANIPCortrophin Gel — Net Revenues
$75.12M+42.1%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%
MiniMed Group logo
MMEDConsumables — Net Sales
$244M+14.6%
Alpha Cognition logo
ACOGProduct Net — Revenue
$3.5M+910%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.49B+81.7%
Enterprise value$31.3B+29.5%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's creon ® — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's creon ® — net sales?
Viatris (VTRS) reported creon ® — net sales of $97.4M in Q1 2026.
How has Viatris's creon ® — net sales changed year-over-year?
Viatris's creon ® — net sales increased by 18.2% year-over-year, from $82.4M to $97.4M.
What is the long-term trend for Viatris's creon ® — net sales?
Over 4 years (2021 to 2025), Viatris's creon ® — net sales has grown at a 4.2% compound annual growth rate (CAGR), from $309.8M to $365.8M.
What does creon ® — net sales mean?
This metric represents the total revenue generated from the sale of a specific branded pharmaceutical product after accounting for returns, allowances, and rebates. It serves as a key indicator of the product's market penetration, pricing power, and demand within the therapeutic category of pancreatic enzyme replacement therapies. Monitoring this figure helps investors assess the revenue contribution and growth trajectory of the company's specialized branded portfolio.